Hayes, S. C., Rye, S., DiSipio, T., Yates, P., Bashford, J., Pyke, C., . . . Eakin, E. (2013). Exercise for health: a randomized, controlled trial evaluating the impact of a pragmatic, translational exercise intervention on the quality of life, function and treatment-related side effects following breast cancer. Breast Cancer Research and Treatment, 137, 175–186.
To evaluate two modes of delivery of an exercise intervention: provided either face-to-face or via the telephone.
Women were randomized to one of three groups: face-to-face exercise, telephone exercise intervention, or usual care. For those in the exercise interventions, the intervention involved 16 sessions, starting weekly and tapering to monthly contact after four months. The exercise prescription was provided in sessions to progress to exercising 45 minutes at least four days per week, incorporating both aerobic and strength-based exercise. Assessments were performed at baseline and six weeks, six months, and 12 months postsurgery.
Patients were undegoing the active antitumor treatment phase of care.
This was a single-blind, randomized, controlled, longitudinal study.
Upper body function and adverse effects, such as menopausal symptoms, pain, anxiety, and depression, improved over time for all patients, with no differences between groups. The adherence rate was 88% in the face-to-face exercise group and 81% in the telephonic intervention group. Patients in both exercise intervention groups showed greater improvement in fatigue symptoms over time (p = 0.032). At the end of the study, fatigue scores improved by 4.9 points in the face-to-face intervention and by 6.8 points in the telephonic group. In the usual care group, fatigue initially got worse; however, scores improved by 4.6 points by 12 months. Sixty-six percent of those in the usual care group also participated in at least 180 minutes of physical activity per week and had an increased level of activity from baseline. Quality of life improved significantly more in the intervention groups over time (p = 0.03)
Findings suggested that delivery of an exercise prescription and instruction via the telephone can be an effective method of delivering an exercise intervention for women with breast cancer. Results of this study support those of others demonstrating improvement in symptoms in all patients over time, but significantly greater improvement in fatigue with exercise interventions.
Findings suggested that providing an exercise prescription might be an effective way to engage patients in exercise, which can reduce symptoms of fatigue. This study demonstrated that providing an exercise program intervention via telephone contact can be as effective as engaging patients in a face-to-face intervention. This suggests that telephonic contact to teach and motivate patients to exercise may be an effective and practical way to deliver an intervention.
Hayek, S.M., Deer, T.R., Pope, J.E., Panchal, S.J., & Patel, V. (2011). Intrathecal therapy for cancer and non-cancer pain. Pain Physician, 14, 219–248.
Databases searched were PubMed, EMBASE, and Cochrane Collaboration.
Search keywords were intrathecal pump for pain, intrathecal infusion, spinal infusion, intrathecal drug delivery system, spinal pump, and intrathecal therapy.
Studies were included in the review if they
Studies were excluded if they
The initial search yielded 812 references; 59 of these were reviewed. A final sample of 20 studies was included. Of these, one randomized trial and four observational studies involved cancer pain. Study quality was evaluated using Agency for Healthcare Research and Quality (AHRQ) criteria for observational studies and Cochrane criteria for randomized controlled trials (RCTs).
For cancer-related pain, the final sample of five studies involved 482 patients with refractory pain and end-stage disease. Samples ranged from 35–202. Five systematic reviews also were included in the review; however, none of these specifically addressed cancer-related pain.
Overall, moderate quality level evidence was found with cancer-related pain. Three out of five of the studies showed 30% or greater pain relief at three months, and four out of five studies showed 50% or greater pain relief at three months. All studies showed improvement in both nociceptive and neuropathic pain control. Studies showed reduced complications with opioids. Complications occurred related to devices, the surgical implant procedure, or other procedure-related aspects in three studies. In one study, miscalculation of pump refill dates resulted in severe pain among five patients.
Long-term efficacy and safety of the intrathecal approach in terminal cancer is justified, and data supports the use of chronic intrathecal morphine for treatment of intractable malignant pain. Problems and complications can occur. Device-related complications and the need for surgical revision appear to have occurred at higher rates in earlier studies compared to more recent studies, which reflects ongoing improvements in techniques and education. Initial assessments of cost effectiveness suggest that cost savings are achieved after two years in comparison to systemic therapy in noncancer pain.
Patient selection and experience with implanted devices are important considerations in decision making for use of intrathecal pain management. Patient and caregiver self-care education is key to the safety and efficacy of this approach.
Hayashi, H., Kobayashi, R., Suzuki, A., Yamada, Y., Ishida, M., Shakui, T., . . . Itoh, Y. (2016). Preparation and clinical evaluation of a novel lozenge containing polaprezinc, a zinc-L-carnosine, for prevention of oral mucositis in patients with hematological cancer who received high-dose chemotherapy. Medical Oncology, 33, 91-016-0795-z.
To evaluate the clinical effect of a newly developed lozenge containing polaprezinc for the prevention of oral mucositis in patients who received conditioning high-dose chemotherapy for hematopoietic stem cell transplantation (HSCT) compared to a polaprezinc (zinc-L-carnosine) suspension in a sodium alginate solution that has been shown to be effective in the prevention of oral mucositis in patients who received radiotherapy or high-dose chemotherapy
Patients were pretreated with either polaprezinc suspension during January 2013 and December 2014 or polaprezinc lozenge during January 2015 and December 2016 for the prevention of oral mucositis. The control group consisted of patients who received high-dose chemotherapy without any premedication during March 2006 and February 2011. The incidence and severity of oral mucositis and its associated symptoms, such as oral pain, were reviewed from medical records and compared among the three groups. The severity of adverse events was graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 3.0.
PHASE OF CARE: Active antitumor treatment
Retrospective cohort comparison
CTCAE, version 3.0
The results showed grade 2 and grade 3 oral mucositis in the no-premedication control group. The polaprezinc suspension group and the polaprezinc lozenge group showed less incidence of grade 2 mucositis, and the overall average grade of oral mucositis was 0.6 for the suspension group and lozenge group. No statistical difference existed in the average grade or incidence rate of oral mucositis between the suspension group and lozenge group.
The newly developed lozenge containing polaprezinc for the prevention of oral mucositis was shown to be highly effective in the prevention of moderate to severe oral mucositis in patients receiving high-dose chemotherapy for HSCT. There was some question about the efficacy of the lozenge preparation when compared to the suspension.
Gender was not clearly identified, and the method of evaluating the grade of mucositis was not clearly described. The lozenge is not a readily available product, developed and compounded for this study. The product has promise if the study is replicated as randomized, controlled trial.
Hayashi, T., Ikesue, H., Esaki, T., Fukazawa, M., Abe, M., Ohno, S., … Oishi, R. (2012). Implementation of institutional antiemetic guidelines for low emetic risk chemotherapy with docetaxel: A clinical and cost evaluation. Supportive Care in Cancer, 20, 1805–1810.
To evaluate the effect of implementation of institutional guidelines (12 mg dexamethasone alone) for low-emetic risk chemotherapy with docetaxel and to estimate the cost savings for all low-emetic risk chemotherapies in a year
All patients with breast cancer received either four courses of FEC therapy (500 mg/m2 5-fluorouracil, 100 mg/m2 epirubicin, and 500 mg/m2 cyclophosphamide) or EC therapy (100 mg/m2 epirubicin and 600 mg/m2 cyclophosphamide, every 21 days) followed by adjuvant docetaxel therapy (70–75 mg/m2) every 21 days for four cycles.
Before implementation of the institutional antiemetic guidelines, group one (41 patients, 151 courses) received 4 mg ondansetron plus 8 mg IV dexamethasone 30 minutes before treatment with docetaxel.
After implementation of the guidelines, group two (56 patients, 205 courses) received 12 mg dexamethasone only. In both groups, 4 mg oral dexamethasone was given twice a day on days 2 and 3 of docetaxel therapy for prevention of docetaxel-related fluid retention.
Effectiveness and adverse effects were compared between groups. With patients who received dexamethasone and ondansetron, investigators evaluated incidence of nausea, vomiting, and adverse reactions with docetaxel retrospectively in the medical records.
Additionally, a cost minimization analysis was performed to assess the economic impact of implementing institutional antiemetic guidelines. The cost comparison looked at 4 mg ondansetron + 8 mg dexamethasone + 100 ml normal saline versus 12 mg dexamethasone + 100 ml normal saline plus the time to prepare the antiemetic guidelines, attending committee, and change order sets.
This study was conducted at a single site, the National Hospital Organization Kyushu Cancer Center (NKCC) in Fukuoka, Japan.
All patients were in active treatment. This study has applications for late effects and treatment.
This was a retrospective cohort study.
The Common Terminology Criteria for Adverse Events, version 3.0, was used to grade adverse drug reactions.
Dexamethasone alone (12 mg) appeared to be as effective in preventing nausea and vomiting as ondansetron and dexamethasone (8 mg) in low-risk emetic chemotherapy with docetaxel, and it was more cost effective.
The use of 12 mg dexamethasone alone for low-risk ematogenic antineoplastic therapies such as docetaxel is recommended in the literature, has shown reasonable effectiveness for preventing nausea and vomiting, and is economically advantageous.
Hayashi, H., Kobayashi, R., Suzuki, A., Ishihara, M., Nakamura, N., Kitagawa, J., . . . Itoh, Y. (2014). Polaprezinc prevents oral mucositis in patients treated with high-dose chemotherapy followed by hematopoietic stem cell transplantation. Anticancer Research, 34, 7271–7277.
To investigate whether polaprezinc is effective in preventing oral mucositis (OM) in patients receiving high-dose chemotherapy and radiation followed by hematopoietic stem cell transplantation (HSCT)
The treatment group received polaprezinc alginate (P-AG) solution rinses four times per day for one month after transplantation. The control group received an azulene oral rinse four times per day for one month after transplantation.
Retrospective study
P-AG decreased the incidence of grade 2 or greater OM. The average grade of OM was lower in the P-AG group. There was a decrease in the amount of moderate to severe pain.
P-AG might be effective in lowering the incidence and severity of OM in patients receiving high-dose chemotherapy and radiation followed by HSCT.
P-AG may help in the prevention of OM, but additional study is warranted before a practice change is recommended.
Hayama, Y., & Inoue, T. (2012). The effects of deep breathing on 'tension-anxiety' and fatigue in cancer patients undergoing adjuvant chemotherapy. Complementary Therapies in Clinical Practice, 18, 94–98.
To investigate the effect of a deep breathing intervention, incorporated within conventional nursing care, on tension-anxiety and fatigue experienced by Japanese women with gynecologic cancer undergoing adjuvant chemotherapy for the first time.
To reduce tension-anxiety and fatigue through deep breathing that incorporated elements of exercise.
The deep breathing intervention was initiated for patients in the intervention group. Each patient received 15 minutes of guidance from the researcher using a DVD and pamphlets. The intervention was performed with nursing assistance pre- and postchemotherapy, with the latter given on the second, fourth, and sixth days. The control group received treatment with the usual chemotherapy and nursing care.
The study used a randomized, controlled trial design.
There were no statistically significant differences between groups in terms of age, diagnosis, or cancer clinical stage or treatment type (p > 0.05). Prechemotherapy data showed no significant differences between the intervention and control groups in the previously mentioned measurement tools. The postchemotherapy tension-anxiety scores were lower in the intervention group (p = 0.01). Both groups showed significant reductions in tension-anxiety scores (both p = 0.00). The postchemotherapy physical and total fatigue scores of the intervention group were significantly lower than those of the control group (physical, p = 0.04; total, p = 0.04).
The study demonstrated that the tension-anxiety and fatigue scores of patients undergoing chemotherapy for gynecologic cancers were lowered when the nurses assisted them with deep breathing for a short period in addition to providing conventional nursing care provided pre- and postchemotherapy. The prominent features of the study were that it used a program that combined three deep breathing techniques and was of short duration (10 minutes).
These are very simple exercises that can be taught to patients and be performed even while they are receiving chemotherapy. In addition to usual nursing care, nurses can contribute to reducing patients’ tension-anxiety and fatigue by assisting them in performing deep breathing.
Hawley, P.H., & Byeon, J.J. (2008). A comparison of sennosides-based bowel protocols with and without docusate in hospitalized patients with cancer. Journal of Palliative Medicine, 11, 575–581.
To determine the efficacy of sennoside-based regimens on the proportion of total days with at least one bowel movement (BM) per day.
During phase I, the first 30 consecutive eligible patients admitted to the ward received docusate plus sennosides (DS) for management of constipation. Dosing was as follows.
During phase II, the next 30 eligible patients with constipation received sennosides only. Dosing was as follows.
Rescue laxatives included lactulose, a suppository, or enema as needed. Only 12 days of bowel protocol were abstracted from the medical record.
This was a nonrandomized, nonblinded, sequential cohort study.
Nursing chart review
Sennosides only produced more BMs than DS.
Adding a stool softener such as docusate does not necessarily produce superior results than those seen with a laxative alone. However, additional randomized, double-blind studies should be conducted before conclusions and evidence into practice are drawn. The usefulness of this study is questionable because of its design and execution issues.
Hawley, P., Hovan, A., McGahan, C.E., & Saunders, D. (2014). A randomized placebo-controlled trial of manuka honey for radiation-induced oral mucositis. Supportive Care in Cancer, 22, 751–761.
To determine if honey swished, held, and swallowed reduced the severity of radiation-induced oral mucositis (ROM)
Honey and placebo gel were provided in 5 mL packets to be taken after salt/bicarbonate oral rinses four times a day after meals and after radiotherapy or approximately the same time on non-treatment days. Participants were to pour the product into their mouth, circulate it for 30 seconds, and swallow. Subjects were instructed not to eat, drink, or rinse their mouth for 30 minutes following swallowing the honey or placebo. Treatment started on the first day of radiation and continued for seven days following the last radiation treatment. Visits to the oral oncology/dentistry department were scheduled weekly until mucositis was resolved. During each visit, an oral examination was done for mucositis severity rating, a brief questionnaire was conducted, and weight was obtained. Unused treatment medication was collected at the last visit to measure compliance.
There were no differences found between the treatment and placebo arms for any of the three outcome assessment scales of mucositis for quality of life, symptom scores, or sialometry. Both the honey (35%) and placebo (43%) groups had lower than expected rates of ≥ grade 3 mucositis.
The honey, when used as directed in this study, did not significantly decrease the severity of ROM. The treatment and placebo groups were well matched, and the blinding was effective. The dropout rate was high (honey: 57%, placebo: 52%, those receiving concurrent chemotherapy: 59%). Most of the dropouts were related to nausea. Patients receiving radiation only had a dropout rate of 48%. Only 48 patients had complete weekly mucositis assessments.
There have been varied outcomes in studies of honey for the treatment of mucositis. Differences in methodology could explain at least part of the variability. In this study, the subjects tolerated the honey poorly because of nausea and gagging, and a couple patients experienced a burning sensation. The authors referenced a study from New Zealand in which a honey mouthwash was used because undiluted honey caused extreme nausea, vomiting, and stinging sensations. Potential reasons for the lack of efficacy seen could be that the mucositis tools may not have had adequate sensitivity to reveal any clinical difference between or the osmotic effect of the honey and placebo. Also, Christian areas like Canada, New Zealand, and Great Britain, where honey does not have any special significance, may differ from Muslim areas that have the Koran’s references to honey’s healing powers.
Hawkins, A.S., Yoo, D.C., Movson, J.S., Noto, R.B., Powers, K., & Baird, G.L. (2014). Administration of subcutaneous buffered lidocaine prior to breast lymphoscintigraphy reduces pain without decreasing lymph node visualization. Journal of Nuclear Medicine Technology, 42, 260–264.
To assess whether anesthetizing the skin with buffered lidocaine before performing breast lymphoscintigraphy reduces pain
Patients were randomly assigned to the control group without lidocaine or the experimental group in which the procedure was preceded by lidocaine injection. Patients were asked to rate their pain levels before and immediately after injections for the procedure. All patients received two injections and were were masked from knowing whether one of them was lidocaine.
No difference in preprocedure pain levels existed between groups. Those who received lidocaine reported less of an increase in pain postprocedure. No difference in lymph node detection existed between groups.
Administration of local anesthetic prior to breast lymphoscintigraphy was associated with lower pain severity after the procedure.
Authors point out that local anesthesia prior to lymphoscintigraphy is not common practice, due to the assumption that any benefit would be outweighed by the pain associated with additional needle sticks. Some patients may feel significant pain during this procedure, and findings from this study suggest an approach to reduce pain with this experience. Authors discuss the findings in terms of the rationale for using a buffered lidocaine solution and implications for practical application and needed lymph node visualization.
Hatoum, H.T., Lin, S.J., Buchner, D., & Cox, D. (2012). Comparative clinical effectiveness of various 5-HT3 RA antiemetic regimens on chemotherapy-induced nausea and vomiting associated with hospital and emergency department visits in real world practice. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer, 20(5), 941–949.
To compare the risk of chemotherapy-induced nausea and vomiting (CINV) events for various 5-HT3 receptor antagonists (RAs) in patients who received moderately (MEC) or highly emetogenic chemotherapy (HEC) by evaluating hospital or emergency department (ED) admissions
Patients with breast cancer who received adjuvant chemotherapy with cyclophosphamide within four months after surgery and patients with lung cancer who were initiated on carboplatin or cisplatin-based chemotherapy within the study time frame (January 1, 2005, through June 20, 2008) were identified using the PharMetrics database. CINV events associated with hospital and ED admissions were extracted using claims with ICD-9-CM codes for nausea, vomiting, or dehydration.
In each cohort, patients were stratified into two groups, one consisting of patients initiated and maintained on palonosetron as the only 5-HT3 RA antiemetic, the other with patients who were initiated on one of the older 5-HT3 RAs and maintained on the same agent or alternated throughout the study duration between the older 5-HT3 RA and palonosetron, either as single agents or in combinations. The use of aprepitant and dexamethasone was used in both cohorts.
The study consisted of 4,868 patients with breast cancer and 7,106 patients with lung cancer (5,414 treated with carboplatin, 1,692 treated with cisplatin).
The median age in all cohorts ranged from 53–65 years.
The breast cancer cohort was 100% female.
The carboplatin-treated lung cancer cohort was 46.5% female and 53.5% male.
The cisplatin-treated lung cancer cohort was 40.3% female and 59.7% male.
The patients in the breast cancer and carboplatin-treated lung cancer cohorts were considered to be treated with moderately emetogenic chemotherapy (MEC). The cisplatin-lung cancer cohort was considered to be treated with highly emetogenic chemotherapy (HEC). The authors did control for differences in age, Charlson comorbidity index (CCI) score, gender (lung cancer cohorts), cyclophosphamide dose per square meter per cycle (breast cancer cohort), and cisplatin and carboplatin treatment days (lung cancer cohorts).
Site and setting type was not indicated. Data was analyzed using pooled patient information from PharMetrics database.
This was a retrospective data analysis.
Based on the results presented by the authors, patients with breast or lung cancer treated with HEC or MEC, when initiated and maintained on palonosetron throughout chemotherapy, experienced significantly reduced risk of hospital- and ED-associated CINV events compared to patients who received other 5-HT3 RA-based regimens. In all three cohorts, the p value was < 0.0001. The results of the data analysis do show superiority of palensetron in reducing such events, but a number of variables and limitations may impact the results.
Antiemetic regimens containing palonosetron may be more effective in reducing severe, uncontrolled CINV than other 5-HT3 agents; however, firm conclusions cannot be drawn because of study design limitations and risks of bias.
The study is helpful because it was an analysis of a large group of patients. It also seeks to provide meaningful conclusions for patients. Although identifying interventions for the reduction of CINV in patients can aid in quality of life and ability to receive treatment in a timely manner, looking at the significance of CINV reduction in preventing serious events such as ED visits or hospitalizations is also important.